Endometriosis has no effective long-term treatment and in few cases, endometriosis serves as a precursor for ovarian cancer. However, efforts are being taken by several treatment providers in developing pills that can help in reducing pain caused by endometriosis. Taking future perspective into consideration, efforts are being made to deliver non-invasive treatment alternatives to women suffering from endometriosis. This in turn, is expected to reduce financial and personal burdens related to endometriosis treatment, thereby improving lives of millions of women suffering from painful and chronic endometriosis disease.

New Endometriosis Treatment Drug Receives FDA Approval

U.S. FDA recently announced approval of American pharmaceutical company, AbbVie’s Orilissa drug, developed for treating pain resulting from endometriosis. The medical care fraternity is increasing their focus towards developing drugs that helps in reducing endometriosis pain. The all-new drug is the first new medical treatment option brought to the market in a decade for reducing endometriosis pain.

The GnRH (gonadotropin-releasing hormone) antagonist activity of elagolix helps in reducing gonadotropin levels, thereby suppressing estradiol—an estrogen type. This in turn, minimizes pain related to endometriosis and spread of lesions. With more than 3 clinical phase trials on over 1,700 women suffering from severe to moderate endometriosis pain, successful results in pain reduction is witnessed.

In addition, the new drug is neither a magic bullet, nor a cure for endometriosis. However, the newly approved pill offers a massive step forward towards the treatment, especially for women suffering from severe pain.

Researchers Find Bioengineering of Human Uterus Beneficial for Endometriosis Treatment

Northwestern Medicine researchers have taken a significant step in bioengineering human uterus for endometriosis treatment, endometrial cancer and uterine-factor infertility. Researchers have concluded that iPS (induced human pluripotent stem) cells could be reprogrammed for turning out to be healthy uterine cells, benefitting in potential placement in uterus. Further, the healthy cells become optimal for auto-transplant, which would not be rejected by immune system of a person. This study is likely to open doors for endometriosis treatment in the forthcoming years.

South Australian Federal Government Makes Heavy Funding for Endometriosis Treatment and Diagnosis

A promised national plan is evolved in South Australia by the Federal Government for developing new ways benefitting in endometriosis treatment and diagnosis. Nearly $2.5Million is funded by the federal government for the research program. The funding also is targeted towards introducing school education program for teaching girls regarding the timely need for medical advice, in times of severe pain during periods, which can possibly lead to endometriosis.

How Will Gene Therapy Prove Lucrative for Endometriosis Treatment

Latest research indicates that suppression of some genes can contribute significantly towards endometriosis disease. Researchers from Yale University are utilizing this finding for creating a new endometriosis treatment that is both non-hormonal and non-invasive. Researchers in Yale University have found out that microRNA let-7b that controls particular gene expression is curbed in women suffering from endometriosis. Soon after this discovery, researchers hypothesized that dispensing let-7b to the patients suffering from endometriosis could help in treating the condition. If the gene treatment proves effective for humans, it can offer non-surgical and non-hormonal endometriosis treatment. Researchers are planning to develop a synthetic form of let-7b, which can be dispensed to patients by means of an injection straight in the abdomen. Growing demand for non-surgical endometriosis treatment is likely to be catered with this therapy in the near future.

Strategic Collaborations for Developing New Non-Hormonal Oral Treatment Addressing Endometriosis

San Francisco –based pharmaceutical companies, twoXAR and Adynxxha have joined forces for development and discovery of the all-new non-hormonal oral treatments aiming at the fundamental causes of endometriosis. The main focus behind this strategic collaboration is to develop a diverse pipeline of promising treatments, in order to cater to the unmet medical needs in inflammatory diseases such as endometriosis. The two companies are planning to introduce non-hormonal treatments with proprietary AI (artificial intelligence) technology of twoXAR that can help in addressing endometriosis as a whole.

To gain further insights on strategic collaborations and innovative therapies in endometriosis treatment market, readers can click here.

Published by Sandali

A former journalist, Sandali is a content marketer with over 5 years of writing experience, across various industries including Food Innovation, Healthcare, and IoT and Technology. Sandali has been weaving corporate stories for organizations through different forms of impactful marketing content. Her key aim is to strategically align well-crafted narratives with business objectives, translating into a powerful communications platform for the company.

Leave a comment

Your email address will not be published. Required fields are marked *